These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2491943)

  • 21. [Digestive absorption of a single loading dose of sodium valproate solution. Comparison of oral and rectal routes].
    Giroud M; Dumas M; Guard O; Escousse A; Dumas R
    Presse Med; 1985 Sep; 14(31):1667-8. PubMed ID: 2932713
    [No Abstract]   [Full Text] [Related]  

  • 22. [Comparative study of valproic acid and sodium valproate (author's transl)].
    Sorel L; Rucquoy-Ponsar M; Willems C; Diepart E; Harmant J
    Acta Neurol Belg; 1981; 81(5):283-90. PubMed ID: 6797226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
    Ben Mahmoud L; Hakim A; Ghozzi H; Atheymen R; Sahnoun Z; Zeghal K
    Rev Neurol (Paris); 2017 Mar; 173(3):159-163. PubMed ID: 28320517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in clearance of sodium valproate with changes in dose.
    Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
    Clin Exp Neurol; 1987; 24():97-103. PubMed ID: 3151881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steady-state valproate pharmacokinetics during long term therapy.
    Eadie MJ; Heazlewood V; McKauge L; Tyrer JH
    Clin Exp Neurol; 1983; 19():183-91. PubMed ID: 6439443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats.
    Reeta KH; Mehla J; Pahuja M; Gupta YK
    Pharmacol Biochem Behav; 2011 Sep; 99(3):399-407. PubMed ID: 21641922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate.
    Wangemann M; Retzow A; Mazur D; Vens-Cappell B
    Int J Clin Pharmacol Ther; 2000 Aug; 38(8):395-401. PubMed ID: 10984013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers.
    Vaz J; Kulkarni C; David J; Joseph T
    Indian J Exp Biol; 1998 Jan; 36(1):112-4. PubMed ID: 9536660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers.
    Kulkarni C; Vaz J; David J; Joseph T
    Indian J Physiol Pharmacol; 1995 Apr; 39(2):122-6. PubMed ID: 7649598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Divalproex-ER pharmacokinetics in older children and adolescents.
    Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
    Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole.
    Boulton DW; Kollia GD; Mallikaarjun S; Kornhauser DM
    J Clin Pharm Ther; 2012 Oct; 37(5):565-70. PubMed ID: 22943745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium.
    Dutta S; Reed RC
    Am J Health Syst Pharm; 2006 May; 63(10):904-6. PubMed ID: 16675645
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical pharmacokinetics of sodium valproate, carbamazepine and phenytoin. Level-dose ration and interactions.
    Levy RH; Moreland TA
    Schweiz Rundsch Med Prax; 1984 Feb; 73(6):159-63. PubMed ID: 6424205
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of carbamazepine and valproate as monotherapy for early epilepsy and single seizures.
    Marson AG; Williamson PR; Taylor S; Maguire M; Chadwick DW
    Neurology; 2006 Nov; 67(10):1872-5. PubMed ID: 17130429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference.
    Cloyd JC; Kriel RL; Jones-Saete CM; Ong BY; Jancik JT; Remmel RP
    J Pediatr; 1992 Apr; 120(4 Pt 1):634-8. PubMed ID: 1552406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valproic acid delayed release (Stavzor).
    Med Lett Drugs Ther; 2009 Apr; 51(1309):27-8. PubMed ID: 19343008
    [No Abstract]   [Full Text] [Related]  

  • 38. Valproate in the treatment of epilepsy in people with intellectual disability.
    Friis ML
    J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():32-5. PubMed ID: 10030429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproate monotherapy in the treatment of epilepsy.
    Am J Med; 1988 Jan; 84(1A):1-41. PubMed ID: 3146218
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic interaction of hydroalcoholic extract of Ocimum sanctum with valproate.
    Sarangi SC; Joshi D; Kumar R; Kaleekal T; Gupta YK
    Epilepsy Behav; 2017 Oct; 75():203-209. PubMed ID: 28867572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.